Signaling from dendritic synapses to the nucleus regulates important aspects of neuronal function, including synaptic plasticity. The neurotrophin brain-derived neurotrophic factor (BDNF) can induce long-lasting strengthening of synapses in vivo and this effect is dependent on transcription. However, the mechanism of signaling to the nucleus is not well understood. Here we describe a microfluidic culture device to investigate dendrite-to-nucleus signaling. Using these microfluidic devices, we demonstrate that BDNF can act directly on dendrites to elicit an anterograde signal that induces transcription of the immediate early genes, Arc and c-Fos. Induction of Arc is dependent on dendrite-and cell body-derived calcium, whereas induction of c-Fos is calcium-independent. In contrast to retrograde neurotrophin-mediated axon-to-nucleus signaling, which is MEK5-dependent, BDNF-mediated anterograde dendrite-to-nucleus signaling is dependent on MEK1/2. Intriguingly, the activity of TrkB, the BDNF receptor, is required in the cell body for the induction of Arc and c-Fos mediated by dendritically applied BDNF. These results are consistent with the involvement of a signaling endosome-like pathway that conveys BDNF signals from the dendrite to the nucleus.
T he neurotrophin brain-derived neurotrophic factor (BDNF) has emerged as a key regulator of synaptic plasticity (1). Deletion of bdnf, or its receptor kinase trkB, or treatment with functionblocking antibodies impairs long-term potentiation (LTP) induced by high-frequency stimulation (2-7). Exogenously applied BDNF can induce LTP at medial perforant path-granule cell synapses in vivo (8), and this effect is blocked by the transcription inhibitor actinomycin D (9). Additionally, BDNF induces genes known to regulate synapse function, such as activity-regulated cytoskeletal (Arc) protein (10-12). Because the effects of BDNF on transcription are frequently explored by bath application, it is not clear if BDNF-mediated transcription is because of activation of TrkB in dendrites, axons, or the cell body (13). If dendritically localized TrkB receptors can regulate gene expression, mechanisms to convey the signal from dendrites to the nucleus, a distance that can be several hundred micrometers, would be required.
How might BDNF transduce a signal from dendrites to the nucleus? Intracellular calcium and the MAPK pathway are among the downstream effectors of BDNF-TrkB (10-12). Several mechanisms for conveying the BDNF signal from dendrites to the nucleus can be envisioned, among them: (i) propagation of a calcium wave to the soma, and subsequent activation of calcium-dependent transcription, as has been previously suggested (14) or (ii) diffusion of signaling molecules from dendrites to the nucleus, as has been suggested for phosphorylated MAPK (6). To determine the mechanisms by which dendritic stimulation leads to transcriptional effects, selective stimulation or inhibition of dendritic signaling is required.
Here we describe the design of a microfluidic device to investigate BDNF-mediated dendrite-to-nucleus signaling. CNS neurons can be cultured in this device and their dendrites can be fluidically isolated from their cell bodies. Using this device, we investigated intradendritic as well as dendrite-to-nucleus signaling. We find that BDNF can act on dendrites to activate gene transcription. This anterograde signaling requires selective roles for calcium, as well as MAPK and TrkB activity, in each compartment. Finally, we find that anterograde neurotrophin signaling from dendrites to the nucleus exhibits marked differences compared with retrograde signaling from axons to the nucleus. Taken together, these data identify a unique mechanism of dendritic signaling that may mediate the effects of dendritic BDNF.
Results
Dendritic Compartmentalization Using a Microfluidic Device. To investigate dendrite-to-nucleus signaling, we developed an approach to selectively stimulate dendrites. Recently, polydimethylsiloxane (PDMS)-based microfluidic culturing devices were developed to fluidically isolate axons from cell bodies, allowing selective stimulation of distal axons (15). These culturing devices comprise two compartments, the cell body compartment and axon compartment, separated by embedded microgrooves (10 μm × 450 μm). Because axons can grow long distances in essentially straight lines, these devices are suitable for compartmentalizing axons. However, because dendrites are branched and substantially shorter, it is not clear whether dendrites would be compatible with a microfluidic culturing system.
We designed a microfluidic device containing two separate compartments (1.5-mm wide, 7-mm long) separated by 7 μm × 75 μm microgrooves ( Fig. 1 A and B) . To determine if dendrites would grow through the microgrooves, embryonic day 18 (E18) rat cortical neurons were plated on poly-D-lysine (PDL)/laminin in the cell body compartment. E18 cortical neuronal dendrites crossed into the neurite compartment as early as day in vitro 7 (DIV7) and exhibited characteristic highly branched processes by DIV14 (Fig. 1C) . Most crossed dendrites arose from cell bodies that were within ∼100 μm of the microgrooves in the cell body compartment (Fig. 1C) . As expected, axons also crossed and were readily detected in the neurite compartment by DIV14 (Fig. 1D) . Similar results were obtained for E18 rat hippocampal neurons, albeit less crossing into the neurite compartment was observed (Fig. S1 ).
Because both axons and dendrites grow into the neurite compartment, we examined dendrites for evidence of synaptic connections. At DIV14, spines were observed in crossed dendrites of GFP-expressing neurons (Fig. 1E) . The average spine density (0.461 ± 0.052 spines per micrometer) of crossed dendrites is similar to previously reported spine densities (16). Additionally, we detected punctate staining for α-actinin, a protein enriched at excitatory synapses (17) (Fig. S1 ). Together, these results demonstrate that dendrites can grow through the 75-μm long microgrooves, exhibit characteristic branched morphology, and form synaptic connections in the neurite compartment.
Fluidic Isolation of Neurites and Cell Bodies. Next, we examined whether the neurite and cell body compartments connected by significantly shortened microgrooves were fluidically isolated. We incubated the neurite compartment with Alexa Fluor-647 hydrazide (20 μg/mL), a low molecular weight fluorescent dye. After 24 h, only a trace amount (∼3%) of the dye was detected in the cell body compartment (Fig. S2 ). This amount of dye leakage was only slightly greater than that determined for the device with 450-μm long microgrooves (∼1%), indicating that despite the sixtimes shorter length of the 75-μm long microgrooves, nearcomplete fluidic isolation can be achieved.
To further assess fluidic isolation, we examined whether cycloheximide (CHX) applied to the neurite compartment can affect protein synthesis in the cell body compartment. Protein synthesis was measured by metabolic labeling with the methionine bioisostere, azidohomoalanine (AHA), which can be labeled with Alexa Fluor-488 alkyne using click chemistry (18). Consistent with a dose-response study, application of CHX (0.5 μM) to the cell body compartment resulted in near-complete inhibition of protein synthesis (Fig. S2) . In contrast, treatment of the neurite compartment with CHX did not affect protein synthesis in the cell body compartment (Fig. S2) . Taken together, these results demonstrate that discrete chemical microenvironments can be maintained with 75-μm long microgrooves.
Intradendritic mRNA Translation Is Required for Dendritic Growth. To examine intradendritic signaling pathways, we first focused on potential functions of dendritic mRNA translation. Dendrites contain mRNAs that encode cytoskeletal proteins (19), suggesting an involvement of local translation in processes such as dendritic growth. However, because it has not been possible to maintain selective application of protein-synthesis inhibitors to dendrites over several days, a role for intradendritic protein synthesis in dendritic growth has not been addressable. To test this idea, we monitored the effect of CHX on basal dendrite growth over 7 d. The cumulative distributions of dendritic length of crossed dendrites after 7 d of CHX treatment demonstrated that neuritic CHX treatment reduced the total dendritic length by 35% compared with vehicle control (median, 847.2 vs. 1,308 μm, respectively) (Fig. S3 ). To rule out the possibility that the effects of CHX on dendritic growth could reflect inhibition of intra-axonal protein synthesis, we stained neurites for ribosomal protein S6. Immunolabeling of DIV9 neurons reveals discrete puncta in dendrites, but not axons (Fig. S3) , indicating the absence of ribosomes in mature axons. This finding is consistent with previous studies demonstrating that mature axons of the central nervous system lack the capacity for protein synthesis (20, 21). These results indicate that intradendritic protein synthesis is required for basal dendritic growth in cortical neurons.
BDNF Induces a Dendrite-to-Nucleus Signal to Regulate Gene Expression. We next asked whether BDNF can elicit a signal that is conveyed from the dendrite to the nucleus. Consistent with previous studies (10, 12), bath application of BDNF induced the expression of the immediate early genes (IEGs) Arc and c-Fos (Fig. S4) . To determine if the transcriptional effects of BDNF can be elicited from dendrites, we selectively applied BDNF to the neurite compartment and measured the expression of Arc and c-Fos in the cell body compartment. Treatment of the neurite compartment with BDNF resulted in a significant induction of Arc (twofold) and c-Fos (fourfold) protein ( Fig. 2 A and B , white arrowheads) and mRNA ( Fig. S4 ) levels in a subset of neurons, which exhibited dendrites that had crossed to the neurite compartment. The increase in Arc and c-Fos protein mediated by neurite application of BDNF was abrogated by the transcription inhibitor actinomycin D (Fig. 2 C and D) . To rule out the possibility that the induction of c-Fos or Arc might reflect activation of TrkB on axonal processes, we selectively applied BDNF to axons of cortical neurons grown in microfluidic devices with 450-μm long microgrooves. Application of BDNF to axons did not induce IEG expression (Fig. S5) , indicating that the effects of BDNF do not reflect retrograde signaling from axons to the nucleus. Importantly, previous studies using Campenot chambers, where the distance between axons and cell bodies is 1 mm, have shown that neurotrophins can convey signals from axons to the nucleus in peripheral system neurons within the time course of our experiments (22, 23).
We next sought to compare the magnitude of gene induction mediated by dendritically applied versus cell body-applied BDNF. Unlike application of BDNF to the neurite compartment, direct application of BDNF to the cell body compartment induced the expression of Arc and c-Fos in nearly all cells (Fig. 2 E  and F) . However, the magnitude of c-Fos induction was nearly identical in both treatment paradigms (Fig. 2H ) and the magnitude of Arc induction mediated by neurite application of BDNF was slightly less than that for cell body application (Fig. 2G ). Taken together, these results demonstrate that BDNF acts on dendrites to generate a signal that is conveyed to the nucleus to induce changes in gene expression. Because BDNF enhances mRNA translation in dendrites (24), we wondered if intradendritic mRNA translation is required for BDNF-mediated dendrite-to-nucleus signaling. Selective application of CHX to the neurite compartment did not affect dendritic BDNF-mediated c-Fos induction. In contrast, direct application of CHX to the cell body compartment attenuated BDNF-induced increases in c-Fos protein levels (Fig. 2I) . Hence, intradendritic mRNA translation is not required for gene induction mediated by BDNF signaling at dendrites. Glutamate Signaling. BDNF can rapidly potentiate excitatory synaptic transmission in cultured cortical and hippocampal neurons by stimulating glutamate release from presynaptic terminals (25, 26) . To determine if glutamatergic transmission is required for dendrite-to-nucleus signaling mediated by dendritic BDNF, cortical neurons were treated with kynurenic acid and MgCl 2 for 48 h before the addition of BDNF to the neurite compartment. These conditions completely blocked c-Fos induction mediated by the GABA A receptor antagonist bicuculline, indicating complete inhibition of glutamatergic signaling (Fig. S6) . Neither Arc nor c-Fos induction by dendritic BDNF was significantly changed in the presence of kynurenic acid and MgCl 2 (Fig. S6) . Thus, glutamatergic transmission is not required for BDNF-mediated dendrite-to-nucleus signaling. Because the basal levels of Arc and c-Fos were reduced in the presence of kynurenic acid and MgCl 2 all subsequent experiments were performed with media containing these compounds.
Intracellular Calcium Is Differentially Required for Dendritic BDNF-
Induced Arc and c-Fos Expression. We next asked if BDNF-mediated dendrite-to-nucleus signaling requires calcium in either the cell body or dendrites. Induction of Arc and c-Fos by cell body application of BDNF was blocked by cell body application of the intracellular calcium chelator BAPTA-AM (Fig. 3A) , consistent with previous studies (12). When BDNF was applied to neurites, Arc induction was blocked by chelating calcium in either the neurite or cell body compartment, indicating a requirement for calcium in both compartments in mediating dendritic BDNF signals. However, induction of c-Fos by dendritic BDNF was independent of calcium in dendrites and was potentiated by chelation of cell body-derived intracellular calcium (Fig. 3B) . The 1.7-fold increase in dendritic BDNF-mediated c-Fos induction in the presence of cell body BAPTA-AM could reflect an inhibitory role for intracellular calcium in regulating c-Fos expression. Taken together, these results demonstrate a differential requirement for intracellular calcium in dendritic BDNF-induced Arc and c-Fos expression.
Dendritically Applied BDNF Induces Arc and c-Fos Through Trk Activity in the Cell Body. We next examined the mechanism by which BDNF signals are conveyed from dendrites to the nucleus. We first asked whether the induction of c-Fos and Arc mediated by dendritic application of BDNF reflects an increase in the release of BDNF from the cell body. To test this idea, we used TrkB-Fc, a membrane-impermeable scavenger of BDNF, to block the effects of extracellular BDNF (6). Application of TrkB-Fc to the neurite compartment before dendritic BDNF stimulation blocked dendritic BDNF-mediated c-Fos and Arc induction (Fig. S7 ). In contrast, application of TrkB-Fc to the cell body compartment did not affect gene expression induced by dendritically applied BDNF (Fig. S7 ). These data argue against a model where dendritic application of BDNF leads to the release of BDNF from the cell body.
Selective application of neurotrophins to PNS axons leads to Trk receptor endocytosis and subsequent retrograde trafficking of neurotrophin-bound Trk to the cell body, where it activates signaling pathways leading to transcription (23, 27-30). To determine if a similar mechanism occurs in dendrites, we first asked if endocytosis is required for BDNF-mediated dendriteto-nucleus signaling. Previous findings demonstrated that the GTPase dynamin is required for TrkB receptor internalization (31) . To assess the requirement of dynamin-mediated endocytosis for dendritic BDNF-induced IEG expression, we used the selective dynamin inhibitor dynasore (32) . Selective treatment of the neurite compartment with dynasore (100 μM) before dendritic BDNF stimulation significantly blocked Arc and c-Fos induction (Fig. S8) .
We next determined if TrkB activity in the cell body is required for BDNF-mediated dendrite-to-nucleus signaling. To test this idea, we sought to pharmacologically inhibit TrkB activity in the cell body after dendritic application of BDNF. Although K252a is commonly used as a Trk inhibitor to investigate the roles of Trks (TrkA, TrkB, and TrkC) in retrograde axonal signaling, it is not selective for Trks (33, 34) . We therefore sought to confirm our results using a panel of structurally distinct Trk inhibitors. The bis-indole Gö6976 is a well-described potent Trk inhibitor (35) . We also considered GW2580, a pyrimidine derivative that was initially described as a highly selective inhibitor of the colony stimulating factor-1 receptor (CSF-1R) (36), a macrophage-enriched kinase that is not expressed at detectable levels in the cortex or hippocampus (37) . A selectivity profile of GW2580 against a panel of over 300 kinases using in vitro competition binding assays revealed marked selectivity for CSF-1R and TrkB, and to a lesser extent, TrkA and TrkC (38) . To determine if GW2580 can inhibit Trk activity in cells, we treated TrkB-expressing human embryonic kidney (TrkB-HEK) cells (39) with increasing concentrations of GW2580 before BDNF stimulation. GW2580 inhibited BDNF-induced Tyr490 phosphorylation of Trk in a dose-dependent manner (EC 50 ∼70 nM) with complete inhibition achieved by 3 μM (Fig. S9) .
We next tested the effects of these inhibitors on dendritic BDNF-induced IEG expression in the microfluidic chambers. Selective application of either K252a (1 μM), Gö6976 (50 nM) or GW2580 (3 μM) to the cell body compartment completely blocked Arc and c-Fos induction mediated by dendritic BDNF (Fig. 4 A and B and Fig. S9 ), indicating that Trk activity in the cell body is necessary for BDNF-mediated dendrite-to-nucleus signaling. In contrast, selective treatment of the neurite compartment with the Trk inhibitors before dendritic BDNF stimulation only partially blocked Arc induction and did not significantly inhibit c-Fos induction (Fig. 4 A and B and Fig. S9 ). Taken together, these data support the idea that dendritic application of BDNF induces TrkB endocytosis and subsequent translocation of TrkB to the cell body, where its activity is required for c-Fos and Arc induction.
BDNF Uses the MEK1/2 Pathway for Dendrite-to-Nucleus Signaling.
We next examined the signaling pathways downstream of BDNFTrkB dendrite-to-nucleus signaling. In PNS neurons, neurotrophins use the MAPK kinase 5 (MEK 5) to elicit retrograde survival signaling (40) . BDNF can activate both MEK1/2 and MEK5 in cortical neurons (41, 12) ; however, it is unclear which of these kinases is required for BDNF-mediated IEG transcription. To determine if the MEK1/2 pathway regulates dendritic BDNF-induced IEG expression, we treated the cell body compartment with the selective MEK1/2 inhibitor PD 0325901 before dendritic BDNF stimulation (42) . PD 0325901 significantly inhibited Arc and c-Fos induction mediated by neuritic application of BDNF (Fig. 4 C and D) . We next sought to determine if p90 ribosomal protein s6 kinases (RSKs), which are major downstream effectors of MEK1/2 in CNS neurons (43) , could regulate BNDF-mediated dendrite-to-nucleus signaling. Treat- suggests that RSK is involved in a negative feedback loop that suppresses the MEK1/2 pathway. Indeed, previous studies have shown that BI D1870 can augment the kinase activity of ERK1/2, which are direct upstream activators of RSK (44) . Taken together, these results demonstrate anterograde dendrite-to-nucleus signaling requires MEK1/2 activity and that RSKs are not downstream effectors in this pathway.
Discussion
The transcriptional effects of BDNF have largely been investigated by bath application of BDNF to cultured neurons. As a result, it is not clear if these effects are a result of the activation of the BDNF receptor TrkB in the cell body or if dendritic TrkB can generate a signal that is conveyed to the nucleus to regulate gene transcription. By selectively applying BDNF to dendrites using microfluidic culturing devices, we find that dendritic TrkB can elicit a signal that is conveyed to the nucleus to induce transcription. Dendritically applied BDNF elicited both a calciumdependent and a calcium-independent signaling cascade, regulating Arc and c-Fos, respectively. BDNF signaling from dendrites to the nucleus requires dynamin-dependent endocytosis in dendrites as well as MEK1/2 and TrkB activity in the cell body. These data suggest BDNF acting at dendrites regulates transcription by inducing TrkB endocytosis and translocation to the cell body, where it activates a MEK1/2 signaling pathway to induce c-Fos and Arc. Taken together, these data demonstrate the existence of a mechanism for conveying signals from dendrites to the nucleus, which may mediate the long-lasting effects of BDNF on synaptic plasticity in vivo. The finding that dendritic BDNF-induced c-Fos expression was calcium-independent was unanticipated, because we found that intracellular calcium was required for the expression of c-Fos following bath application of BDNF. Additionally, previous studies have suggested that BDNF induces c-Fos expression in a calcium-dependent manner (14). One explanation for this discrepancy is that the signaling pathway induced by dendritically localized TrkB is calcium independent, and was masked by the global activation of TrkB. Indeed, numerous signaling proteins are expressed in specific compartments in the cell (45) , and may therefore not be accessible to TrkB depending on its localization in cells. Our results point to the potential differences between TrkB pathways elicited in the cell body and dendrites, and highlight the importance of selective stimulation of dendritic TrkB using approaches such as the microfluidic devices described here.
There are at least three differences between anterograde neurotrophin-mediated dendrite-to-nucleus and retrograde axonto-nucleus signaling that are worth noting. First, whereas retrograde axonal signaling requires Trk activity in the axon (30), dendrite-to-nucleus signaling does not necessarily require Trk activity in dendrites. Second, whereas neurotrophin-mediated axon-to-nucleus signaling uses MEK5 to mediate nuclear responses (40), BDNF-mediated dendrite-to-nucleus signaling uses MEK1/2 to mediate Arc and c-Fos induction. The specific MAPK pathway that is activated most likely determines which downstream signaling pathways are activated to mediate transcription of specific genes. Finally, local mRNA translation promotes retrograde signaling in axons (46) , and intradendritic mRNA translation is dispensable for the induction of c-Fos by dendritically applied BDNF.
What does the requirement for Trk activity in the cell body for dendritically mediated BDNF induction of IEGs suggest about the mechanism of neurotrophin-mediated dendrite-to-nucleus signaling? A major mechanism for axon-to-nucleus signaling in PNS neurons is the signaling endosome model (47) . In this model, the neurotrophin-bound Trk receptor is endocytosed in distal axons and is then translocated as an endosome to the cell body, where it activates its downstream effectors, leading to gene transcription. Our data showing the requirement for Trk activity in the cell body and dynamin-mediated endocytosis in dendrites for BDNF-mediated dendrite-to-nucleus signaling is consistent with a novel dendrite-derived signaling endosome. It will be important to image BDNF-TrkB endosome trafficking from dendrites to the cell body, and to determine if these signaling endosomes contribute to BDNF-mediated changes in synaptic plasticity in a physiological context. Previous studies have shown that theta-burst stimulation induces the release of endogenous BDNF from mossy fibers, as well as Schaffer collaterals onto the dendrites of CA3 and CA1 pyramidal neurons, respectively, and this mediates long-lasting changes in potentiation or depression (3, 48, 6, 49) . Moreover, a recent study demonstrated that release of BDNF from cortical axons onto dendrites of medium spiny neurons in the dorsal striatum induced postsynaptic LTP (50) . It is conceivable that dendritically derived BDNF-TrkB endosomes have a role in these pathways.
We envision the investigation of other potential dendrite-tonucleus signaling pathways using the microfluidic device described here. Because the microfluidic platform is compatible with live cell imaging, intracellular trafficking of signaling molecules from dendrites to the cell body can be imaged following selective dendritic synapse activation using these devices. Recently, Schuman and colleagues described a different microfluidic device to investigate synaptic signaling (51) . In this device, neurons are cultured in two compartments, and project axons and dendrites toward a narrow central perfusion chamber. Both of these devices provide an opportunity to investigate the molecular pathways that couple dendritic stimulation with changes in gene expression.
Materials and Methods
The polydimethylsiloxane microfluidic devices with 75-μm microgrooves were fabricated as previously described (15). The preparation of the microfluidic devices for compartmentalization of dendrites are described in SI Materials and Methods. The materials used and detailed methods are described in SI Materials and Methods. 
Supporting Information
Cohen et al. 10.1073/pnas.1012401108
SI Materials and Methods

Preparation of Microfluidic Devices for Compartmentalization of
Dendrites. The cleaned, sterilized, and dry devices were reversibly affixed to poly-D-lysine (PDL) (Millipore) -coated coverslips (Assistant; 50 × 24 mm; two devices per coverslip) and then placed in a 10-cm plastic Petri dish [Preparation of PDL coated coverslips: Nitric acid-treated coverslips were coated with 1 mg/mL PDL in 0.1 M borate buffer for ∼12 h at 37°C in a humidified tissue-culture (TC) incubator containing 5% CO 2 , washed three times with sterile water, and air dried in a laminar flow hood]. A solution of 5 μg/mL laminin (Trevigen) in Neurobasal (NB) medium (Invitrogen) was added to the four reservoirs of the device. Devices were coated with laminin for at least 3 h at 37°C in the TC incubator and then washed three times with plain NB medium. After the last wash, plain NB was removed from the reservoirs by aspiration (medium in the main channels where the cells will reside was not removed) and plating medium [NB supplemented with 10% FBS (Atlanta Biologicals), 2 mM Glutamax (Invitrogen), 1 mM sodium pyruvate (Invitrogen), 100 IU penicillin, and 100 μg/mL streptomycin (Invitrogen)] was added to the reservoirs (150 μL per reservoir). The Petri dish containing the devices was then placed in a square Petri dish (100 × 15 mm) with 10 mL of sterile water, which significantly decreased the evaporation rate of media from the devices, and then placed in the TC incubator before plating the neurons (usually 72 h). Culture medium for neurons was NB supplemented with NS21 (1), 2 mM Glutamax, penicillin/streptomycin. Conditioned culture medium was media from E18 rat cortical neurons (8 × 10 6 cells) cultured in parallel in a 10-cm dish.
Compartmented Neuronal Culture in the Microfluidic Device. Embryonic day (E) 18 rat cortical (∼1.5 × 10 5 cells) or hippocampal (∼7 × 10 4 cells) neurons were plated in the cell body side. After ∼15 min, plating medium was added (150 μL per reservoir). Medium was exchanged with culture medium after 5 to 12 h. On day in vitro (DIV) 3, one-half of the medium was replaced with culture medium containing 20 μM 5-fluorodeoxyuridine.
Nucleofection of Rat Cortical Neurons. Immediately after dissociation, E18 rat cortical neurons (5 × 10 6 cells) in 100 μL Rat Neuron Nucleofector solution (Lonza) were nucleofected with a vector expressing GFP (8 μg) according to the manufacturer's protocol (Amaxa Nucleofector program: G-013). Nucleofected cells were then plated in the microfluidic devices as described.
Immunofluorescence. Neurons plated on glass coverslips in the microfluidic device were fixed in 4% (wt/vol) paraformaldehyde (Electron Microscopy Sciences) and 4% (wt/vol) sucrose in PBS (pH 7.4) for 20 min at room temperature. The neurons in the device were washed once with PBS containing 10 mM glycine, three times with PBS, and permeabilized with 0.2% TX-100 in PBS for 5 min. The chambers were then carefully removed from the coverslips and neurons were blocked for 60 min at room temperature in 10% (wt/vol) BSA in PBS containing 0.1% TX-100 (PBS-T) and labeled with primary antibodies in 3% BSA in PBS-T overnight at 4°C. Coverslips were washed three times with PBS and incubated with Alexa Fluor-conjugated goat secondary antibodies (Invitrogen) for 1 h at room temperature. After incubation with secondary antibodies, coverslips were washed three times with PBS, once with water, and then mounted on a glass microscope slide (VWR) with Prolong Gold with DAPI (Invitrogen). The primary antibodies used in this study were as follows: chicken and mouse anti-MAP2 (1:2,000; Millipore, AB5543 and MAB378), mouse anti-TAU-1 (1:1,000; Millipore, MAB3420), mouse anti-α-actinin (1:500; Sigma, A7811), chicken anti-GFP (1:2,000; Abcam, ab13970), mouse anti-Arc (1:100; Santa Cruz Biotechnology, sc-17839), rabbit anti-c-Fos (1:200; Cell Signaling Technology, 2250), rabbit antiribosomal protein S6 (1:100; Cell Signaling Technology, 2217), rabbit anti-pTyr490 Trk (1:1,000; Cell Signaling Technology, 9141), and mouse anti-β-actin (1:500; Genscript, A00702).
Fluorescence in Situ Hybridization. Probe synthesis: ∼500 bp PCR products comprising of the Arc and c-Fos coding and 3′ untranslated region were transcribed into antisense or sense RNA using the digoxigenin (DIG)-11-UTP RNA labeling kit with T7 RNA polymerase (Roche). FISH of Arc and c-Fos using these probes was performed as follows: Neurons plated on glass coverslips in the microfluidic device were fixed in 4% (wt/vol) paraformaldehyde in PBS (pH 7.4) for 15 min at room temperature. The neurons were washed twice in 2× SSC (Ambion) and incubated in freshly prepared acetic anhydride solution [100 mM Hepes (pH 8.0), 0.25% acetic anhydride (Sigma)] for 10 min at room temperature. The neurons were rinsed briefly in DEPCtreated water (Fisher) and permeabilized with 1:1 methanol/acetone solution for 5 min at −20°C. The neurons were washed in 2× SSC and incubated in hybridization buffer [40% formamide (Fisher), 2× SSC, 10% dextran sulfate (Millipore), 1× Denhardt's solution (Invitrogen) 100 μg/mL Escherichia coli tRNA (Roche), 1 mg/mL salmon sperm DNA (Sigma), and 20 mM vanadyl ribonucleoside complexes solution (Sigma)] for 1 h at room temperature. The chambers were then carefully removed from the coverslips and neurons were incubated with DIGlabeled RNA probes (2 ng/mL Arc, 4 ng/mL c-Fos, denatured by heating for 5 min at 90°C) in hybridization buffer overnight at 56°C. After hybridization, neurons were washed in 2× SSC and incubated in 2× SSC containing 10 μg/mL RNase A (Invitrogen) for 15 min at 37°C. Neurons were washed extensively as follows: 2× SSC for 10 min at room temperature, 0.5× SSC for 10 min at room temperature, 0.5× SSC for 30 min at 56°C, and 0.5× SSC for 10 min room temperature (twice). Endogenous peroxidase activity was inactivated by incubating neurons in 1× SSC containing 3% H 2 O 2 (Acros) for 15 min at room temperature. Neurons were washed three times in 1× SSC, followed by Tris buffered saline (TBS), and incubated with sheep anti-DIG-POD antibody (1:400; Roche) and chicken anti-MAP2 in blocking buffer (PerkinElmer) overnight at 4°C. Neurons were washed three times in TBS-0.05% tween-20 and the RNA signal was then detected using the TSA plus amplification system (PerkinElmer). Coverslips were washed three times with TBS-0.05% tween-20 and incubated with Alexa Fluor conjugated goat secondary antibodies (Invitrogen) for 1 h at room temperature. After incubation with secondary antibodies, coverslips were washed three times with TBS, once with water, and then mounted on a glass microscope slide with Prolong Gold with DAPI.
Inhibitors. Unless otherwise noted, all inhibitors were prepared as 1,000× stocks in DMSO (Sigma). The following inhibitors were used: Cycloheximide (CHX) (Calbiochem), Actinomycin D (Calbiochem), BAPTA-AM (Sigma), K252a (Calbiochem), PD 0325901 (Calbiochem), BI D1870 (Symansis), Bicuculline (Sigma), Kynurenic acid (Sigma), dynasore (Sigma), Gö6976 (EMD Biosciences), and GW2580 (BioVision), TrkB-Fc (R&D Systems).
Image Acquisition and Data Analysis. Fluorescent and phasecontrast images were acquired on a Nikon Eclipse TE2000-E microscope equipped with a CoolSnap HQ2 CCD camera. Within each experiment, exposure times were kept constant and in the linear range throughout. When using the 40× and 100× oilimmersion objectives, stacks of images were taken and deconvoluted using AutoDeblur X (Media Cybernetics). All fluorescence intensity values (arbitrary units, AU) were calculated using NIS-Elements Advanced Research version 3.1 software (Nikon). The fluorescence intensity/volume levels for Arc and c-Fos were determined by creating a binary mask from the MAP2 and DAPI signal, respectively, and then determining the intensity in all stacks under the mask. All graphs and statistical P values were generated using Prism version 4.0. All data are presented as mean ± SEM; n values are represented on all graphs and defined in legends.
Assays for Fluidic Isolation. Cortical neurons were cultured in microfluidic devices and on DIV13, the medium from the reservoirs in the cell body compartment was replaced with 160 μL per reservoir of conditioned culture medium. Next, 20 μg/mL Alexa Fluor-647 hydrazide in conditioned culture medium (80 μL per reservoir) was added to the neurite compartment. After 24 h, phase-contrast and fluorescence images were acquired. The mean fluorescence intensity adjacent to the microgrooves in the cell body and neurite compartments was determined (neurite: 11562.92 AU, cell body: 330.81 AU). The background fluorescence intensity (2.44 AU) was calculated from a device not incubated with the dye. Assays to measure fluidic isolation of CHX were performed using click chemistry and fluorescent visualization of protein synthesis. On DIV9, the culture medium for E18 rat cortical neurons grown in microfluidic devices was exchanged with click medium (methionine-free DMEM, 1× B27, 2 mM Glutamax, 10 μM cysteine, 230 μM sodium pyruvate, penicillin/ streptomycin) for 1 h. The medium was replaced with click medium containing 50 μM azidohomoalanine (AHA) and either vehicle or 0.5 μM CHX (Calbiochem) for 2 h (two devices per condition). For selective treatment of CHX in the neurite compartment, 160 μL per reservoir of the click medium containing AHA was first added to the cell body compartment and then 80 μL per reservoir of the click medium containing AHA and either vehicle or CHX was added to the neurite compartment. After metabolic labeling with AHA, neurons were fixed, permeabilized, and blocked with 2% BSA in PBS. Conjugation of the Alexa Fluor-488 alkyne to incorporated AHA was achieved using the Click-iT Kit (Invitrogen). Neurons were immunostained for MAP2 and the fluorescence intensity for the AHA signal was determined.
Analysis of Protein Synthesis and Dendritic Morphology. E18 cortical neurons were grown in microfluidic devices and on DIV7 the medium was removed from all devices. For neuritic CHX treatment, 160 μL per reservoir of conditioned culture medium was first added to the cell body compartment and then 80 μL per reservoir of conditioned culture medium containing vehicle or 0.5 μM CHX in conditioned medium was added to the neurite compartment (seven devices per condition). Medium in all reservoirs was replaced every 24 h. After 7 d, cells were fixed, permeabilized, blocked, and immunostained for MAP2. For analysis of dendritic morphology, images of MAP2-immunolabeled dendrites were recorded using a 20× objective (N.A. 0.5) on a Leica DM IRB microscope and analyzed using NeuroLucida. A total of 75 dendrites from 14 devices were analyzed. Image acquisition and data analysis were performed blind to experimental conditions.
TrkB-Expressing Human Embryonic Cells and Inhibitor Treatments.
TrkB-expressing human embryonic (TrkB-HEK) cells were cultured in DMEM (Invitrogen) supplemented with 10% FBS (VWR). Inhibitor treatment and detection of phosphorylated Trk by Western blot: TrkB-HEK cells were cultured in serum-free DMEM containing NS21 for 3 h and then treated with either K252a (1 μM) or Gö6976 (50 nM) or increasing concentrations of GW2580 or vehicle control for 30 min. Cells were then stimulated with brain-derived neurotrophic factor (BDNF) (25 ng/ mL) for 15 min. Cells were then placed on ice and washed with cold (4°C) PBS and lysed in RIPA buffer [50 mM Tris (pH 8.0), 150 mM NaCl, 1% Nonidet P-40, 0.1% SDS] containing protease (Roche) and phosphatase (Sigma) inhibitor mixtures. Lysates were clarified by centrifugation (13 K, 10 min, 4°C) and proteins were resolved by 4% to 12% SDS/PAGE, transferred to nitrocellulose (Bio-Rad), blocked in 5% (wt/vol) nonfat milk, probed with the appropriate primary and secondary antibodies, and detected by enhanced chemiluminescence (GE Life Sciences).
BDNF Stimulation and Inhibitor Treatment of Rat Cortical Neurons.
E18 cortical neurons were grown in microfluidic devices and on DIV8, one-third of the medium was replaced with conditioned medium containing 1 mM kynurenic acid (Sigma) and 10 mM MgCl 2 (Sigma). On DIV10, neurons were pretreated with vehicle or indicated inhibitor for 1 h and then stimulated with 100 ng/mL BDNF (R&D Systems) for 2 h (two devices per condition). For selective treatment of BDNF in the neurite compartment, 160 μL per reservoir of conditioned medium was first added to the cell body compartment and then 80 μL per reservoir of conditioned medium containing BDNF was added to the neurite compartment, thereby creating a hydrostatic gradient. After BDNF treatment, cells were fixed, permeabilized, blocked, and immunostained for Arc, c-Fos, and MAP2. Image stacks were acquired using the 40× oil-immersion objective and deconvoluted. The fluorescence intensity/volume levels for Arc and c-Fos of cells that exhibited crossed dendrites were determined. (D-G) On DIV10, Gö6976 (50 nM) or GW2580 (3 μM) or vehicle control was added to the indicated compartment followed by the addition of BDNF (100 ng/mL) to the neurite compartment for 2 h. Cells were fixed and immunolabeled with antibodies against Arc, c-Fos, and MAP2. The fluorescence intensity of Arc and c-Fos in cell bodies of neurons that clearly exhibited crossed dendrites was determined. The error bars represent SEM, ***P < 0.0001 (unpaired, twotailed t test); n values listed above the bars represent the number of cell bodies analyzed.
